MiNK Therapeutics adds Dr. John Holcomb to board

MiNK Therapeutics reported a change in its board of directors.

Rhea-AI Filing Summary

MiNK Therapeutics reported a change in its board of directors. On September 23, 2025, the company’s Board elected Dr. John Holcomb as a Class II director, with his initial term ending at the 2026 annual meeting of stockholders. This adds new expertise to the board without changing its overall structure.

In connection with his election, Dr. Holcomb received a stock option to purchase 4,174 shares of MiNK common stock under the 2021 Equity Incentive Plan and the non-employee director compensation program. The option has a 10-year term, an exercise price set at the closing market price on the grant date, and vests in three equal annual installments as long as he continues to serve. As a non-employee director, he is also eligible for cash and potential additional equity compensation under the same program.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did MiNK Therapeutics (INKT) disclose?

MiNK Therapeutics disclosed that on September 23, 2025, its Board elected Dr. John Holcomb as a Class II director, with an initial term expiring at the 2026 annual meeting of stockholders.

What equity compensation did Dr. John Holcomb receive from MiNK Therapeutics (INKT)?

Dr. Holcomb was granted an option to purchase 4,174 shares of MiNK Therapeutics common stock under the 2021 Equity Incentive Plan and the non-employee director compensation program.

What are the key terms of Dr. Holcomb’s stock option at MiNK Therapeutics (INKT)?

The option has a 10-year term, a per-share exercise price equal to the closing price of MiNK’s common stock on the Nasdaq Capital Market on the grant date, and vests over three years in equal annual installments, conditioned on Dr. Holcomb maintaining a service relationship with MiNK.

Will Dr. John Holcomb receive additional compensation as a MiNK Therapeutics (INKT) director?

Yes. As a non-employee director, Dr. Holcomb will receive cash and possible additional equity compensation in line with MiNK’s non-employee director compensation program.

Did MiNK Therapeutics (INKT) disclose any related-party transactions with Dr. Holcomb?

MiNK stated that there are no arrangements or understandings with any other person regarding Dr. Holcomb’s selection as a director and no transactions between Dr. Holcomb and MiNK requiring disclosure under Item 404(a) of Regulation S-K.

Did MiNK Therapeutics (INKT) issue a press release about Dr. Holcomb’s appointment?

Yes. MiNK issued a press release on September 29, 2025 announcing Dr. Holcomb’s appointment to the Board, which is included as Exhibit 99.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/29/2025 - 09:14 AM Learn about SEC filing dates

false000184022900018402292025-09-232025-09-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 23, 2025

MiNK Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40908	82-2142067
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
149 Fifth Avenue Suite 500
New York, New York				10010
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 212 994-8250

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		INKT		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 23, 2025, the Board of Directors (the “Board”) of MiNK Therapeutics, Inc., (“MiNK”) elected Dr. John Holcomb to become a Class II director of MiNK with an initial term that expires at MiNK’s annual meeting of stockholders in 2026.

In connection with his election to the Board, Dr. Holcomb was granted an option to purchase 4,174 shares of MiNK’s common stock pursuant to MiNK’s 2021 Equity Incentive Plan and MiNK’s non-employee director compensation program. The option has a per-share exercise price equal to the closing price of MiNK’s common stock on the Nasdaq Capital Market on the date of grant and a 10-year term, and it vests over three years in equal annual installments (provided Dr. Holcomb maintains a service relationship with MiNK through each such vesting date). As a non-employee director, Dr. Holcomb will also receive cash and possible additional equity compensation paid by MiNK pursuant to its non-employee director compensation program. There are no arrangements or understandings between Dr. Holcomb and any other person pursuant to which Dr. Holcomb was selected as a director, and there are no transactions between Dr. Holcomb and MiNK that would require disclosure under Item 404(a) of Regulation S-K.

On September 29, 2025, MiNK issued a press release announcing Dr. Holcomb’s appointment to the Board. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release dated September 29, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	September 29, 2025	By:	/s/ Jennifer S. Buell, Ph.D.
			Jennifer S. Buell, Ph.D., CEO